Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports promising results for alopecia universalis treatment using a combination of systemic methotrexate and low-dose corticosteroids with topical minoxidil, though monitoring for side effects is necessary.

This study presents a case of idiopathic alopecia mucinosa achieving complete remission with minocycline treatment and reviews the existing literature on the condition.

This case report describes a 70-year-old woman whose obstructive sleep apnea resolved after the removal of a testosterone-producing ovarian tumor, supporting the theory that testosterone influences OSA in women.

This review explores the role of FGFR2b-signaling in the pathogenesis of acne, highlighting its influence on sebaceous gland physiology and the effects of anti-acne agents like isotretinoin.

This review discusses recent findings on the mechanisms driving bullous pemphigoid, highlighting epitope spreading and the roles of regulatory T cells, and reports no new experimental results.

This review discusses photobiomodulation as a potential treatment for hair loss, highlighting its safety and possible effectiveness but noting cost, protocol standardization, and expectation management as limitations; it reports no new clinical results.

This review found that, among 103 patients treated off-label with abrocitinib for conditions beyond atopic dermatitis, favorable clinical outcomes were reported for most cases, except one isolated case involving erythematotelangiectatic rosacea.

This review discusses the clinical and pathologic features of follicular contact dermatitis, highlighting neomycin as a potential cause, and reports no new clinical results.

This study found that antifungal therapy significantly reduced pustules in patients with refractory acne, indicating a potential role for Malassezia infection in such cases.

In this study, researchers found that dermoscopy revealed specific features in Malassezia folliculitis, such as folliculocentricity and perilesional erythema, which can aid in its identification and potentially distinguish it from acne vulgaris.

This review discusses the potential role of JAK inhibitors, like ruxolitinib, as emerging therapeutic agents in dermatology, but reports no new clinical results.

This study reported that a single treatment using macrofocused ultrasound energy with a 2 mm transducer significantly reduced pore count, pore volume, and pore index in 34 Thai subjects with enlarged facial pores over a 6-month period, with no adverse events observed.

This review analyzed literature on primary cutaneous lymphomas involving the scalp, finding that scalp involvement in these cases often leads to non-scarring focal alopecia and may indicate more aggressive disease.

This case report describes a rare presentation of nevus comedonicus following the lines of Blaschko, treated with oral isotretinoin and other therapeutic measures, resulting in a reduction of episodic painful cystic lesions.

This study found that combining minoxidil 0.1% and dutasteride 0.01% applied topically after microneedling was significantly more effective than using dutasteride alone with microneedling in improving female pattern hair loss in 40 female patients.

This review discusses acne tarda, emphasizing its commonality in women and potential links to endocrinological disorders, but reports no new clinical findings and suggests collaboration with specialists for management.

This article summarizes highlights from the 40th Annual DNA Convention, covering various dermatology topics, but it does not report new clinical results.

This review discusses various therapeutic agents for alopecia areata, categorized by efficacy and safety, and highlights the lack of curative treatments and long-term outcome studies.

New treatments like JAK inhibitors show promise for reversing alopecia areata.

This review discusses the efficacy and safety of topical sensitizers for treating alopecia areata and reports no new clinical results; it emphasizes advancements in pediatric use, molecular mechanisms, and targeted delivery methods.

This abstract compiles a list of medical syndromes and conditions related to tongue abnormalities and other systemic features but reports no new research findings.

Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.

This review discusses various diseases associated with hidradenitis suppurativa, including obesity, arthritis, and pyoderma gangrenosum, but reports no new clinical results and calls for further research.

This review explores the efficacy and outcomes of using JAK inhibitors for treating alopecia areata, noting advancements in understanding the disease's pathomechanisms and suggesting that JAK inhibitors may offer targeted therapeutic benefits by blocking specific inflammatory pathways involved in this chronic condition.

In this observational study, researchers found that mini-pulse oral corticosteroids effectively reduced hair loss in alopecia areata patients who did not respond to topical therapies, though early-onset patients and those with hypothyroidism were less likely to benefit.

This study found that oral cyclosporine was more effective and had fewer side effects than betamethasone minipulse therapy for treating alopecia areata.

This article outlines treatment options and counseling recommendations for pediatric alopecia areata, highlighting shared decision-making based on disease severity and patient goals, with newer treatments like JAK inhibitors and dupilumab requiring attention to cost and side effects.

This study found that magnesium supplementation significantly improved overall quality of life in women with polycystic ovary syndrome, but did not significantly affect acne, alopecia, or abnormal uterine bleeding.

This study found that topical betamethasone dipropionate was more effective than topical latanoprost in reducing the area and promoting hair regrowth in patients with localized alopecia areata, though latanoprost was considered safer.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.